Apyx Medical Corporation (NASDAQ:APYX) Given Consensus Rating of “Moderate Buy” by Brokerages

Apyx Medical Corporation (NASDAQ:APYX) has been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $6.60.

Several equities research analysts recently commented on the company. Zacks Research raised Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a research report on Wednesday, June 24th. Finally, HC Wainwright assumed coverage on shares of Apyx Medical in a research note on Monday, July 13th. They issued a “buy” rating and a $7.00 target price for the company.

Apyx Medical Price Performance

Shares of NASDAQ:APYX opened at $3.05 on Wednesday. The company has a current ratio of 5.68, a quick ratio of 4.53 and a debt-to-equity ratio of 3.19. Apyx Medical has a 1 year low of $1.70 and a 1 year high of $5.08. The business has a fifty day simple moving average of $3.69 and a 200 day simple moving average of $3.80. The firm has a market cap of $128.48 million, a price-to-earnings ratio of -15.25 and a beta of 1.31.

Apyx Medical (NASDAQ:APYX) last issued its earnings results on Thursday, August 6th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Apyx Medical had a negative return on equity of 76.60% and a negative net margin of 14.78%.The firm had revenue of $13.88 million for the quarter, compared to the consensus estimate of $13.18 million. As a group, sell-side analysts predict that Apyx Medical will post -0.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Apyx Medical

Institutional investors and hedge funds have recently modified their holdings of the business. Nantahala Capital Management LLC boosted its holdings in Apyx Medical by 2.5% in the second quarter. Nantahala Capital Management LLC now owns 3,338,048 shares of the company’s stock worth $7,511,000 after purchasing an additional 80,000 shares in the last quarter. Osaic Holdings Inc. bought a new position in Apyx Medical during the second quarter valued at about $50,000. Vanguard Group Inc. raised its holdings in Apyx Medical by 3.6% during the third quarter. Vanguard Group Inc. now owns 1,528,947 shares of the company’s stock valued at $3,272,000 after buying an additional 53,175 shares in the last quarter. Franklin Resources Inc. acquired a new stake in shares of Apyx Medical in the third quarter worth about $59,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Apyx Medical in the third quarter worth about $28,000. Institutional investors and hedge funds own 55.33% of the company’s stock.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.